VORASIDENIB

Information current as at: 1 June 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Voranigo®
Form and strength:: Please search for and view the meeting agenda from the relevant meeting for more information
Condition/indication: (therapeutic use): Astrocytoma or oligodendroglioma
Listing requested:: Please see meeting agenda for more information
Funding program:: Please see meeting agenda for more information
Request authority level:: Please see meeting agenda for more information
PBAC submission type:: New PBS listing (–)
Comment:: --
Submission sponsor:: SERVIER LABORATORIES (AUST.) PTY. LTD.
Other PBAC consideration:: VORASIDENIB

Submission received for:: March 2026 PBAC meeting
Opportunity for consumer comment:: Open 19/11/2025 and close 21/01/2026 (see PBS Website)
PBAC meeting:: Held on 11/03/2026
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: 09/04/2026
Lodgement of required documentation:: 17/04/2026
Acceptance of complete documentation:: Accepted
Agreement to listing arrangements:: Commenced on 11/05/2026
Status:: Finalised
7Government processes:: Commenced on 22/05/2026
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Not yet published

Public Summary Document:

Not yet available

Case ID: a1198

Page last updated: 31 May 2026

v.9.19